Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04379869
Recruitment Status : Recruiting
First Posted : May 8, 2020
Last Update Posted : June 29, 2020
Sponsor:
Information provided by (Responsible Party):
Neuren Pharmaceuticals Limited

Brief Summary:
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of NNZ-2591 when administered to healthy volunteers.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: NNZ-2591 Phase 1

Detailed Description:

This study is in two stages:

Stage 1: A First-in-Human (FIH), single dose escalation study of oral NNZ-2591 in healthy volunteers to establish safety, tolerability and pharmacokinetic parameters.

Stage 2: A First-in-Human (FIH), multiple dose escalation study of oral NNZ-2591 in healthy volunteers to establish safety, tolerability and pharmacokinetic parameters.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Stage 1: Single ascending dose with 3 dose cohorts Stage 2: Multiple ascending doses with 2 dose cohorts
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Combined Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of NNZ-2591 in Healthy Volunteers
Actual Study Start Date : May 29, 2020
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Arm Intervention/treatment
Experimental: NNZ-2591 SAD Cohort 1
Single Ascending Dose (SAD) of oral NNZ-2591 in healthy volunteers
Drug: NNZ-2591
Single ascending dose and multiple ascending doses of NNZ-2591

Experimental: NNZ-2591 SAD Cohort 2
Single Ascending Dose (SAD) of oral NNZ-2591 in healthy volunteers
Drug: NNZ-2591
Single ascending dose and multiple ascending doses of NNZ-2591

Experimental: NNZ-2591 SAD Cohort 3
Single Ascending Dose (SAD) of oral NNZ-2591 in healthy volunteers
Drug: NNZ-2591
Single ascending dose and multiple ascending doses of NNZ-2591

Experimental: NNZ-2591 MAD Cohort 1
Multiple Ascending Dose (MAD) of oral NNZ-2591 in healthy volunteers
Drug: NNZ-2591
Single ascending dose and multiple ascending doses of NNZ-2591

Experimental: NNZ-2591 MAD Cohort 2
Multiple Ascending Dose (MAD) of oral NNZ-2591 in healthy volunteers
Drug: NNZ-2591
Single ascending dose and multiple ascending doses of NNZ-2591




Primary Outcome Measures :
  1. Safety and Tolerability measured through Adverse Events /Serious Adverse Events [ Time Frame: 25 days ]
    The frequency and severity of Adverse Events in healthy volunteers administered single and repeated oral doses of NNZ-2591


Secondary Outcome Measures :
  1. Pharmacokinetic - Cmax [ Time Frame: 17 days ]
    Maximum observed plasma concentration (Cmax) of NNZ-2591

  2. Pharmacokinetic - AUC∞ [ Time Frame: 17 days ]
    Area under the concentration-time curve from time 0 to infinity of NNZ-2591

  3. Pharmacokinetic - Tmax [ Time Frame: 17 days ]
    Time to Cmax of NNZ-2591

  4. Pharmacokinetic - t1/2 [ Time Frame: 17 days ]
    Terminal elimination half-life



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female subjects aged 18 to 65 years, inclusive;
  2. Weight at screening and admission between 45 kg and 100 kg;
  3. Body mass index (BMI) between 18.0 and 32.0 kg/m2 inclusive;
  4. Healthy as determined by the Investigator based on pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead electrocardiogram (ECG);
  5. Negative tests for Hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV) and human immunodeficiency virus (HIV)-1 and HIV-2 antibody at screening;
  6. Clinical laboratory test results up to >1.5 x Lower Limit of Normal (LLN) or <1.5 x Upper Limit of Normal (ULN) at screening and admission and deemed not clinically significant by the Investigator;
  7. Negative screen for alcohol and drugs of abuse at screening and admission;
  8. Non-smokers or ex-smokers (must have ceased smoking >3 months prior to screening visit);

    If female:

  9. Woman with no childbearing potential by reason of surgery or at least 1year post- menopause (i.e., 12 months post last menstrual period), and menopause confirmed by follicle-stimulating hormone (FSH) testing;
  10. If of childbearing potential, using an effective nonhormonal method of contraception (intrauterine device; condom or occlusive cap [diaphragm or cervical or vault caps]; true abstinence; or vasectomized male partner (provided that he is the sole partner of that subject and had a vasectomy ≥30 days prior to screening) for the duration of the study and up to one month after the last investigational medicinal product (IMP) administration;
  11. Negative serum pregnancy test at screening and negative urine pregnancy test on admission (women of childbearing potential only);

    If male:

  12. Using an effective method of contraception (condom) if sexually active with a female partner of child-bearing potential; true abstinence; or vasectomy ≥30 days prior to screening) throughout the study and for one month after the last IMP administration.

Exclusion Criteria:

  1. Subjects who have a clinically relevant history as determined by the Investigator, or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders;
  2. Fridericia's correction factor for QT (QTcF) > 450 ms for male participants and >470ms for female participants or history of QT interval prolongation.
  3. Have a clinically relevant surgical history, as determined by the Investigator;
  4. Have a history of relevant atopy or drug hypersensitivity;
  5. Have a history of alcoholism or drug abuse;
  6. Consume more than 21 standard drinks a week for males and more than 14 standard drink if female [1 standard drink is any drink containing 10g of alcohol, regardless of container size or alcohol type].
  7. Have a significant infection or known inflammatory process on screening or admission;
  8. Have acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea, heartburn) at the time of screening or admission;
  9. Have used any prescription or non-prescription medicines within 2 weeks of admission, unless in the investigator's opinion will not affect determination of safety or other study assessments. Occasional paracetamol use (up to 2g/day is permitted);
  10. Have received any investigational drug within 30 days prior to screening;
  11. Have used tobacco or nicotine products within 3 months of screening
  12. Have donated or received any blood or blood products within the 3 months prior to screening;
  13. Cannot communicate reliably with the investigator;
  14. Are unlikely to co-operate with the requirements of the study;
  15. Are unwilling or unable to give written informed consent.

    If female:

  16. Pregnancy or breast-feeding;
  17. Woman of childbearing potential not willing to use an accepted effective contraceptive method or using hormonal contraceptives;

    If male:

  18. Not willing to use an accepted effective method of contraception.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04379869


Contacts
Layout table for location contacts
Contact: Nicola Norton +61 (0) 414 416 034 nnorton@linear.org.au

Locations
Layout table for location information
Australia, Western Australia
Linear Clinical Research, The Queen Elizabeth II Medical Centre Recruiting
Nedlands, Western Australia, Australia, 6009
Sponsors and Collaborators
Neuren Pharmaceuticals Limited
Investigators
Layout table for investigator information
Study Director: James Shaw Neuren Pharmaceuticals
Principal Investigator: Jasmine Williams Linear Clinical Research
Layout table for additonal information
Responsible Party: Neuren Pharmaceuticals Limited
ClinicalTrials.gov Identifier: NCT04379869    
Other Study ID Numbers: NEU-2591-HV-001
First Posted: May 8, 2020    Key Record Dates
Last Update Posted: June 29, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Neuren Pharmaceuticals Limited:
Healthy Volunteers